FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer
FDA granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.) for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Drugs & Pharmacology | Grants